* Biomerica Inc BMRA.OQ BMRA.O is expected to show a fall in
quarterly revenue when it reports results on August 30
(estimated).
* The Irvine, California-based company is expected to report a
23.6% decrease in revenue to $2.083 million from $2.73 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Biomerica Inc is for a
loss of 10 cents per share. For the same quarter last year, the
company reported a loss of 4 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Biomerica Inc
is $11, about 61.4% above its last closing price of $4.25.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Feb. 28 2021 -0.03 -0.08 -0.15 Missed -87.5
Nov. 30 2020 -0.10 -0.10 -0.13 Missed -33.3
Aug. 31 2020 -0.08 -0.08 -0.14 Missed -75
May. 31 2020 -0.07 -0.07 -0.04 Beat 40
Feb. -0.07 -0.06 -0.09 Missed -38.5
29 2020
Nov. 30 2019 -0.08 -0.05 Beat 37.5
Aug. 31 2019 -0.06 -0.06 -0.05 Beat 16.7
May. 31 2019 -0.08 -0.08 Met 0
This summary was machine generated August 27 at 12:31 GMT. All
figures in US dollars unless otherwise stated